Oveporexton improves sleep outcomes in patients with narcolepsy

The orexin receptor 2‐selective agonist oveporexton improved sleep‐ and wakefulness‐related measures in a dose‐dependent fashion relative to placebo in adults with narcolepsy type 1, a Phase 2 study has found. Most adverse events associated with oveporexton were mild to moderate, with no reports of suicidality.

Publication Details

Journal
The Brown University Psychopharmacology Update
Published
2025-08-04
DOI
https://doi.org/10.1002/pu.31348
Primary Topic
Sleep and Wakefulness Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Oveporexton improves sleep outcomes in patients with narcolepsy

The Brown University Psychopharmacology Update
Sleep and Wakefulness Research
article

Oveporexton improves sleep outcomes in patients with narcolepsy

article en

Abstract

The orexin receptor 2‐selective agonist oveporexton improved sleep‐ and wakefulness‐related measures in a dose‐dependent fashion relative to placebo in adults with narcolepsy type 1, a Phase 2 study has found. Most adverse events associated with oveporexton were mild to moderate, with no reports of suicidality.

The Brown University Psychopharmacology UpdateVol. 36(9)
Openalex Percentile: Top 81%
Sleep and Wakefulness Research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Oveporexton improves sleep outcomes in patients with narcolepsy · The Brown University Psychopharmacology Update (2025) | TGRS Research Map | TGRS